TMEM106B Haplotype as Genetic Modifier in FTD — Mechanism and Therapeutic Exploitation
Background and Rationale
Validation experiment to elucidate how the TMEM106B protective haplotype modifies FTD disease course, with implications for therapeutic target identification.
Protocol: (1) CRISPR-engineered iPSC lines: isogenic GRN+/- (FTD risk) with either TMEM106B risk or protective haplotype (4 lines total). Differentiate to cortical neurons, microglia, and astrocytes. (2) Multi-omic profiling: RNA-seq, ATAC-seq, proteomics (TMT-16plex), lysosomal activity assays (DQ-BSA, Magic Red cathepsin), lipid profiling (lipidomics). (3) GRN-/- x TMEM106B-/- double knockout mice: behavioral, neuropathological, and transcriptomic analysis at 6, 12, and 18 months. (4) Human genetics: TMEM106B haplotype stratified analysis in FTD cohort (n=2000 GRN carriers) for age of onset, disease progression, and survival.
...TMEM106B Haplotype as Genetic Modifier in FTD — Mechanism and Therapeutic Exploitation
Background and Rationale
Validation experiment to elucidate how the TMEM106B protective haplotype modifies FTD disease course, with implications for therapeutic target identification.
Protocol: (1) CRISPR-engineered iPSC lines: isogenic GRN+/- (FTD risk) with either TMEM106B risk or protective haplotype (4 lines total). Differentiate to cortical neurons, microglia, and astrocytes. (2) Multi-omic profiling: RNA-seq, ATAC-seq, proteomics (TMT-16plex), lysosomal activity assays (DQ-BSA, Magic Red cathepsin), lipid profiling (lipidomics). (3) GRN-/- x TMEM106B-/- double knockout mice: behavioral, neuropathological, and transcriptomic analysis at 6, 12, and 18 months. (4) Human genetics: TMEM106B haplotype stratified analysis in FTD cohort (n=2000 GRN carriers) for age of onset, disease progression, and survival.
Primary Outcome: Lysosomal function metrics (pH, cathepsin activity, degradative capacity) in GRN+/- iPSC neurons with protective vs. risk TMEM106B haplotype. Success Criteria: Protective haplotype restores lysosomal pH to within 0.3 units of wild-type AND delays clinical onset by >3 years in human cohort. Model System: iPSC-derived neurons + GRN-/-;TMEM106B-/- mice + human cohort. Expected Timeline: 24 months. Estimated Cost: $1.5M.
This experiment directly tests predictions arising from the following hypotheses:
- Transcriptional Autophagy-Lysosome Coupling
- Autophagosome Maturation Checkpoint Control
- Lysosomal Enzyme Trafficking Correction
- Lysosomal Calcium Channel Modulation Therapy
- Mitochondrial-Lysosomal Contact Site Engineering
Experimental Protocol
Phase 1: Patient Cohort Assembly and Genetic Characterization (Months 1-6)• Recruit n=500 FTD patients with confirmed pathogenic mutations (C9orf72, MAPT, GRN) and n=500 age-matched controls
• Extract genomic DNA from peripheral blood samples using Qiagen QIAamp DNA Blood Maxi Kit
• Perform whole genome sequencing (30x coverage) on Illumina NovaSeq 6000 platform
• Genotype TMEM106B rs1990622 and rs3173615 variants using TaqMan assays in triplicate
• Construct TMEM106B haplotypes (protective vs. risk) based on linkage disequilibrium patterns
• Collect detailed clinical phenotyping including age of onset, disease duration, CDR-FTLD scores
Phase 2: Functional Mechanism Investigation (Months 7-18)
• Generate iPSC lines from n=24 FTD patients (12 protective haplotype, 12 risk haplotype)
• Differentiate iPSCs to cortical neurons using dual SMAD inhibition protocol (21-day protocol)
• Perform TMEM106B protein quantification via Western blot and immunofluorescence microscopy
• Measure lysosomal pH using LysoSensor Yellow/Blue DND-160 ratiometric imaging
• Assess autophagy flux using LC3-II/LC3-I ratios and p62 degradation assays
• Conduct proteomics analysis of lysosomal fractions using LC-MS/MS (Orbitrap Fusion)
Phase 3: Therapeutic Target Validation (Months 19-30)
• Design TMEM106B overexpression vectors for protective isoform delivery
• Test small molecule modulators of lysosomal function (chloroquine, bafilomycin A1, trehalose)
• Perform high-throughput screening of 10,000 compound library for TMEM106B modulators
• Validate lead compounds in patient-derived neuronal cultures (n=48 wells per condition)
• Measure neuroprotective effects via cell viability assays, neurite outgrowth, and synaptic markers
• Conduct RNA sequencing to identify downstream pathway modulation
Expected Outcomes
Genetic Association: TMEM106B protective haplotype (rs1990622-A/rs3173615-C) will delay FTD onset by 3-5 years compared to risk haplotype (p<0.001, hazard ratio 0.6-0.8)
Protein Expression: Protective haplotype carriers will show 40-60% higher TMEM106B protein levels in neurons compared to risk haplotype carriers (p<0.01, Cohen's d>0.8)
Lysosomal Function: Neurons with protective haplotype will maintain lysosomal pH 0.3-0.5 units lower than risk haplotype neurons (pH 4.2 vs 4.7, p<0.001)
Autophagy Enhancement: Protective haplotype will show 2-3 fold increased autophagy flux measured by LC3-II turnover and p62 clearance (p<0.01)
Therapeutic Modulation: Lead compounds will restore lysosomal function in risk haplotype neurons to protective levels (>80% rescue, IC50<10μM)
Survival Benefit: TMEM106B overexpression will improve neuronal survival by 50-70% in FTD patient cultures under stress conditions (p<0.001)Success Criteria
•
Statistical Significance: Achieve p<0.001 for primary genetic association with minimum effect size Cohen's d>0.8 and hazard ratio confidence interval excluding 1.0
• Sample Size Adequacy: Complete analysis with >90% of planned sample size (n>450 per group) and <5% missing data for primary endpoints
• Functional Validation: Demonstrate statistically significant differences (p<0.01) in at least 3 of 4 functional assays (protein levels, lysosomal pH, autophagy flux, cell survival)
• Therapeutic Proof-of-Concept: Identify minimum 3 lead compounds with IC50<10μM that rescue functional deficits by >50% in risk haplotype neurons
• Reproducibility: Replicate key findings across at least 3 independent iPSC lines per haplotype group with consistent effect directions
• Clinical Relevance: Establish correlation coefficient >0.6 between in vitro functional measures and clinical phenotype severity in patient samples